Bifidobacterium bifidum strain used for production of bifido-containing products

FIELD: food industry.

SUBSTANCE: Bifidobacterium bifidum 79-94 strain possessing acid-forming activity, antagonistic activity with regard to pathogenic and opportunistic microorganisms is deposited in the State Collection of Normal Microflora Microorganisms of Federal State Academic Institution "G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology" under the Federal Service for Consumer Rights Protection and Human Welfare (Rospotrebnadzor) under Registration Number 231 and may be used for production of cultured milk products, food products, hygienic and cosmetic aids, dietary supplements and bacterial preparations.

EFFECT: invention allows to produce cultured milk, fermented and non-fermented food products, hygienic and cosmetic aids, dietary supplements and bacterial preparations ensuring normalisation of microflora in the human organism.

2 tbl, 5 ex

 

The invention relates to the food, cosmetic, biotech and medical industries, in particular used for the preparation of fermented milk, fermented and non-fermented food, hygiene and cosmetics, dietary supplements and bacterial preparations.

Due to unfavorable environmental conditions, stress, prolonged antibiotic, radiotherapy and chemotherapy, dysbiosis resulting from illness, an increasing number of people suffering from disorders of the normal microflora. For the treatment and prevention of these disorders is gaining attention as drugs, with probiotic action, and food products containing bifidobacteria.

In the human intestine, basically, there are 5 species of bifidobacteria - B. bifidum, B. longum, B. adolescentis, B. breve, and B. infantis. Of them with the greatest frequency in the biocenosis detected species B. bifidum and B. longum. Species B. adolescentis is more common in adults, and the species B. breve and B. infantis - predominantly in infants.

Well-known foreign mono - and combination preparations-eubiotics and dairy products, including bifidobacteria species B. bifidum, B. lonqum, B. adolescentis, B. breve (patent 2336886, patent 2411008, France; patent 637297, Switzerland; patent 2134179, p is the awning 2421066, Germany; patent 05227946, patent 0430642, Japan; patent 4645667, U.S. patent 6063935, Japan, the patent 5922375, U.S. patent 5902743, U.S. patent 6746672, U.S. patent 6548057, USA). In our country for the preparation of bacterial preparations, dietary supplements, medicinal products-dietary use of domestic strains of Bifidobacterium species B. bifidum 1,791,792; B. lonqum B379M, I-2, I-4; B.adolescentis MC-42, G 7513; .breve 79-119; B.infantis 79-43 (copyright certificate №343588, RF patent 1347221, RF patent 849779, RF patent 2108383, RF patent 2152993, patent 863639, RF patent 2120991, RF patent 2078814, RF patent 2111248).

The quality of medicinal products and drugs is largely due to the properties of the producer strain - specific activity and adaptability. A large range of biologically active and technologically advanced strains of bifidobacteria makes possible the development of new mono - and integrated products for medical nutrition and bakpreparatov, capable of providing high colonization resistance of the human intestine, to restore the normal microflora and reduce the incidence of various intestinal infections.

The present invention is to obtain a strain of microorganism of the species B. bifidum 79-94 with high biological activity, resistance to environmental conditions, with a stabilizing kislotoobrazovanie in the whole temperature range R is Suite cells, antagonistically active against pathogenic and conditionally pathogenic microorganisms proliferating on artificial nutrient media.

Strain Bifidobacterium bifidum 79-94 isolated from the contents of the intestines of healthy infant and deposited in the Public collections of the normal microflora (HCNM) fsri mniam them. Hingamisega of the CPS No. 231.

The inventive strain can be used in the production of dairy products, fermented foods, such as kvass, beer, etc., non-fermented foods, such as juices, drinks, etc., starter cultures for the preparation of dairy products and biologically active additives to food. Strain Bifidobacterium bifidum 79-94 can be widely used for the production of hygienic and cosmetic products, such as: creams, lotions, wipes, Soaps, powders, tampons, nourishing masks, gels, feminine sanitary pads, skin milk, various powders, etc.

In addition, the strain of Bifidobacterium bifidum 79-94 can be used in the production of bacterial preparations, in the form of candles, oral, and other tools.

The technical result of the claimed invention to provide a strain of Bifidobacterium bifidum 79-94, which can be used as biologically active substances in the composition of kilomoles is s, fermented and non-fermented food starters, hygiene and cosmetics, dietary supplements and bacterial preparations. Strain Bifidobacterium bifidum 79-94 has biologically and technologically important properties, such as high acid activity and its ability to increase microbial biomass in a short period of cultivation. Strain Bifidobacterium bifidum 79-94 antagonistically active against pathogenic and conditionally pathogenic microorganisms. This will allow the use of Bifidobacterium bifidum 79-94 as a biologically active component in the composition of different probiotic means of ensuring the normalization of microbiocenosis of the human body, including the gastrointestinal and urogenital tracts, skin and mucous membranes of the skin, and broaden the Arsenal of similar means.

Cultural and morphological properties of the strain.

Cells are gr+ polymorphic sticks with bifurcation or thickening 1-2 ends, in a liquid nutrient medium to grow over the entire height of the volume, except for the zone of aerobiosis. Separately grown colonies on hepatic nutrient medium have cometabolism form colonies. Logarithmic growth phase ends at 12-24 hours of cultivation.

Physical and biochemical properties of the strain.

Non-sporulating, still gone anaerobic. Optimal the temperature of cultivation 38,0±0.5°C. Catalase does not form, gelatine does not dilute. Sprayway glucose with the formation of acetic and L + lactic acid, without the formation of gas, sakissa environment growing up to a pH of 4.2 and 3.8. Ferments lactose, fructose, galactose, sucrose. Not ferments sorbitol, arabinose, salicin, inulin, cellobiose, xylose, mannose, beckons. Strain skachivat milk to 24-36 hours

Strain Bifidobacterium bifidum 79-94 has an antagonistic activity against pathogenic and conditionally pathogenic microflora (table 1).

Table 1
Antagonistic activity of strain .bifidum 79-94
StrainThe zone of growth inhibition of the test cultures mm/M±M
Sh.sonneiSh.flexneriE.coliS.aureusPr.vulgaris
Century bifidum 79-9420±2.616±2,212±1,822±1,024±2,8

The strain is expanding microbial mass and increase hydrolysate-dairy medium (GM), Bifidum environment (BF), thus producing acid (table 2).

The maximum strain accumulates microbial mass to 12-24 hours, reaching in 1 ml lg 8-9 microbial cells that are actively producing acid.

Thus, the proposed strain B. bifidum 79-94 tech, as propagated in various nutrient media with the accumulation of production of biomass with a high concentration of bifidobacteria; has acid-forming activity and antagonistic activity against pathogenic and conditionally pathogenic microorganisms.

Fermented milk, fermented, unfermented food, hygiene, cosmetics, dietary supplements and bacterial preparations containing strain B. bifidum 79-94, can be widely used in food, medical, biotechnology and cosmetic industries.

The ability of strain B. bifidum 79-94 to increase the biomass in the nutrient medium in a short period of cultivation, acid-forming activity, antagonistic activity against pathogenic and conditionally pathogenic microflora, as well as other useful for the human body properties, typical for the species B. bifidum, make possible the use of the strain in the various corrective means of therapeutic and prophylactic purposes.

Example 1. The use of strain B. bifidum 79-94 in the composition biologist who Cesky supplements.

1 passage: lyophilized strain B. bifidum 79-94 in the amount of 0.1 g dry biomass contribute in tubes with nutrient medium and titrated by the method of tenfold dilution to 10-9. Incubated at a temperature 38,0±0,5° before the formation of visible growth in the last dilutions.

2 passage: a grown culture of 10-7-9dilutions up to 10% contribute to the nutrient medium and cultured at a temperature 38,0±0.5°C for 12-24 h before formation of the dense growth of the visible area of aerobiosis.

3 passage: the biomass in an amount up to 10% of the volume contribute to the accumulation and cultivate 12-24 h at 38,0±0.5°C, to obtain a biomass content of live bifidobacteria not less than 108/ml.

The result is biologically active additive, which is a liquid concentrate with a high, not less than 108/ ml, content of bifidobacteria.

Example 2. The use of strain B. bifidum 79-94 for the preparation of fermented and non-fermented foods.

1 passage: lyophilized strain B. bifidum 79-94 in the amount of 0.1 g dry biomass contribute in tubes with nutrient medium and titrated by the method of ten-fold dilutions up to 10-9. Incubated at 38,0±0.5°C prior to the formation of visible growth in the last dilutions.

2 passage: a grown culture of 10-7-9dilutions up to 10% contribute to the nutrient medium and will antivirous at a temperature 38,0±0.5°C for 12-24 h before formation of dense growth with a highly visible area of aerobiosis.

3 passage: the biomass in an amount up to 10% of the volume contribute to the accumulation and cultivate 12-24 h at 38,0±0.5°C, to obtain a biomass content of live bifidobacteria not less than 108/ml.

Obtaining a fermented or non-fermented food: grown biomass bring in food raw materials (milk, juices, beer, kvass, etc. up to 10% of the volume, mix and pour into containers. The result is a product with a concentration of live bifidobacteria not less than 106/ml.

Example 3. The use of strain B. bifidum 79-94 for the preparation of a fermented milk product.

1 passage: lyophilized strain introduced into the environment of cultivation and titrated by the method of ten-fold dilutions up to 10-9. Incubated at 38,0±0.5°C prior to the formation of visible growth in the last dilutions. Or dry lyophilized biomass of bifidobacteria contribute in 1-2 doses in the tube with 30 ml of culture medium. Cultivated at a temperature 38,0±0.5°C, to obtain a biomass content of live bifidobacteria not less than 107/ ml.

2 passage: a grown culture of strain B. bifidum 79-94 of the last dilution or test-tube with the increased biomass contribute to the accumulation of up to 10% and cultured at a temperature 38,0±0.5°C, to obtain a biomass containing bifidobacteria not less than 108/ ml.

3 passage: polucen the Yu biomass of the strain B. bifidum 79-94 up to 10% bring in sterile milk, cultured to the formation of a clot (milk product). The number of passages No. 2 may be increased depending on the volume of production.

Example 4. The use of strain B. bifidum 79-94 to obtain bacterial preparations.

The culture of the strain of the 1st or 2nd passage (example 1) contribute to the nutrient medium, cultured at a temperature 38,0±0.5°C to obtain the biomass of bifidobacteria with the contents of living cells is not less than 108in 1 ml. To the obtained biomass add a protective environment drying (saharso-gelatin medium, skim milk). The resulting suspension is poured into ampoules, vials and other containers, frozen at minus 35-45°C and lyophilizers from the frozen state in a vacuum drying apparatus. The resulting preparation contains not less than 107living cells of bifidobacteria. The content of bifidobacteria is consistent with the scientific and technical documentation on similar bifidobakterii drug "Bifidumbacterin dry" and is sufficient to use the funds received as a drug - eubiotics.

Example 5. The use of Bifidobacterium bifidum 79-94 to get hygienic and cosmetic products. The culture of the strain of the 1st or 2nd passage (example 1) contribute to the nutrient medium, cultured at a temperature 37-8 degrees Celsius to obtain the biomass of bifidobacteria with the contents of living cells is not less than 10 81 ml, dried by spray or freeze drying.

The obtained dry biomass of bifidobacteria strain Bifidobacterium bifidum 79-94 enter into the composition of the nutrient cream in an amount of not more than 1% by volume.

Safety: with the introduction of three outbred white mice dose per os microbial culture of strain in an amount of 5×X107SOME of the animal's death, deviations in health status of the mice during the observation period is not marked.

Strain Bifidobacterium bifidum 79-94 used to obtain bifidobacteria products deposited in the Public collections of the normal microflora (HCNM) fsri mniam them. G.N. Of g.n.gabrichevsky of Rospotrebnadzor, registration No. 231.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: method involves adding an additive containing biomass of microorganisms into waste water with initial pH 5.5. The microorganisms used are at least one of the following types: Rhodotorula glutiuius in amount of 14-6 mg/m3, Trihoderme viridae in amount of 23-1 mg/m3, Chaetomium globosum in amount of 25-15 mg/m3.

EFFECT: invention enables to increase treatment efficiency by accelerating the process.

3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to medical microbiology and a method of differentiating Francisella tularensis subsp. mediasiatica bacteria. The method involves testing the analysed culture using an indicator and a substrate in form of discs with nitrocefin. The discs are first washed with distilled water and then placed on the analysed strains. Further, incubation is carried out at 37°C for 5-10 minutes. Results are determined from the colour of the discs. Francisella tularensis strains of the Central Asian subspecies do not change the colour of the discs, while strains of other subspecies colour the discs red.

EFFECT: invention can be used for rapid analysis when differentiating Francisella tularensis subsp mediasiatica.

1 dwg, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, particularly genetic and protein engineering, as well as a method of producing recombinant human C-peptide. The disclosed method involves culturing an Escherichia coli producing strain, breaking down bacterial cells by disintegration, separating "inclusion bodies" containing a hybrid protein, dissolution thereof in a buffer containing urea and dithiothreitol, renaturating and purifying the renatured hybrid protein, disintegration thereof with trypsin and carboxypeptidase B, separation via chromatography on SP-sepharose, followed by purification and obtaining the end product.

EFFECT: method enables to obtain C-peptide with high output and purity of not less than 95% from wastes formed when producing recombinant human insulin.

4 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to genetic engineering and microbiological industry, as well as a genetic structure for exposing protein on the Yarrowia lipolytica yeast cell wall surface. The disclosed structure has a promoter, a terminator, a signal sequence, a selective marker, a nucleotide sequence which encodes an immobilised protein, and a nucleotide sequence which encodes an amino acid sequence containing an amino acid sequence selected from a group of sequences given in the list of sequences under number SEQ ID NO:1 or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, or SEQ ID NO:6.

EFFECT: invention simplifies the process of purifying the protein produced by the cell and can be used in microbiological synthesis of proteins.

7 dwg, 11 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to genetic engineering and microbiological industry, as well as a genetic structure for exposing protein on the Yarrowia lipolytica yeast cell wall surface. The disclosed structure has a promoter, a terminator, a signal sequence, a selective marker, a nucleotide sequence which encodes an immobilised protein, and a nucleotide sequence which encodes an amino acid sequence containing an amino acid sequence selected from a group of sequences given in the list of sequences under number SEQ ID NO:1 or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, or SEQ ID NO:6.

EFFECT: invention simplifies the process of purifying the protein produced by the cell and can be used in microbiological synthesis of proteins.

7 dwg, 11 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to genetic engineering and microbiological industry, as well as a genetic structure for exposing protein on the Yarrowia lipolytica yeast cell wall surface. The disclosed structure has a promoter, a terminator, a signal sequence, a selective marker, a nucleotide sequence which encodes an immobilised protein, and a nucleotide sequence which encodes an amino acid sequence containing an amino acid sequence selected from a group of sequences given in the list of sequences under number SEQ ID NO:1 or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, or SEQ ID NO:6.

EFFECT: invention simplifies the process of purifying the protein produced by the cell and can be used in microbiological synthesis of proteins.

7 dwg, 11 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to genetic engineering and microbiological industry, as well as a genetic structure for exposing protein on the Yarrowia lipolytica yeast cell wall surface. The disclosed structure has a promoter, a terminator, a signal sequence, a selective marker, a nucleotide sequence which encodes an immobilised protein, and a nucleotide sequence which encodes an amino acid sequence containing an amino acid sequence selected from a group of sequences given in the list of sequences under number SEQ ID NO:1 or SEQ ID NO:2, or SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, or SEQ ID NO:6.

EFFECT: invention simplifies the process of purifying the protein produced by the cell and can be used in microbiological synthesis of proteins.

7 dwg, 11 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The invention relates to a method of obtaining L-lysine using Escherichia coli bacteria containing versions of the dapA gene of B. subtilis bacteria.

EFFECT: invention enables to obtain L-lysine with high efficiency.

6 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The invention relates to a method of obtaining L-lysine using Escherichia coli bacteria containing versions of the dapA gene of B. subtilis bacteria.

EFFECT: invention enables to obtain L-lysine with high efficiency.

6 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to molecular biology and chemistry. Disclosed is a method for homogenising a solution of magnetic particles on which DNA is absorbed. The present invention is used in laboratory diagnosis when preparing samples for a polymerase chain reaction, for extracting DNA from biopreparations and removing or neutralising extraneous impurities.

EFFECT: obtaining DNA with purity which is suitable for amplification reaction.

6 dwg, 1 ex

Phytotranquiliser // 2452507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry for the purpose of preparing drugs. The drug contains powdered herbs (valerian, motherwort, melissa, Greek valerian) and/or their dry concentrates and Vitamin C.

EFFECT: drug extends the range of tranquilisers for compensation of individual intolerance to certain components of known preparations and provides body recovery from stress consequences, enhances immunity, protects against free radicals accompanying stress.

3 cl, 3 ex

Phytotranquiliser // 2452507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry for the purpose of preparing drugs. The drug contains powdered herbs (valerian, motherwort, melissa, Greek valerian) and/or their dry concentrates and Vitamin C.

EFFECT: drug extends the range of tranquilisers for compensation of individual intolerance to certain components of known preparations and provides body recovery from stress consequences, enhances immunity, protects against free radicals accompanying stress.

3 cl, 3 ex

Phytotranquiliser // 2452507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry for the purpose of preparing drugs. The drug contains powdered herbs (valerian, motherwort, melissa, Greek valerian) and/or their dry concentrates and Vitamin C.

EFFECT: drug extends the range of tranquilisers for compensation of individual intolerance to certain components of known preparations and provides body recovery from stress consequences, enhances immunity, protects against free radicals accompanying stress.

3 cl, 3 ex

Phytotranquiliser // 2452507

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry for the purpose of preparing drugs. The drug contains powdered herbs (valerian, motherwort, melissa, Greek valerian) and/or their dry concentrates and Vitamin C.

EFFECT: drug extends the range of tranquilisers for compensation of individual intolerance to certain components of known preparations and provides body recovery from stress consequences, enhances immunity, protects against free radicals accompanying stress.

3 cl, 3 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

Antibacterial agent // 2452506

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely creating a herbal agent showing antibacterial action. The herbal antibacterial agent contains powdered pear fruits in amount 0.1 g to 20.0 g and dry grinded raw plants or dry plant extract in amount 0.1 g to 2.0 g specified in a group: wild camomile, roots of common licorice, blossom of small-leaved lime, leaves of red raspberry, leaves and blossom of sow-foot, herb and blossom of common thyme, root of sweatweed, leaves of garden sage. The antibacterial agent may be presented in the form of a powder, capsules, tablets, granules, sachets, and lozenges. The antibacterial agent is non-toxic and shows additional therapeutic properties: antispasmodic, antipyretic, antitussive, disintoxication and antiallergic.

EFFECT: agent is applicable both independently, and in the integrated therapy, promotes a soft and physiologic antibacterial response, reduced side effects and disbiotic disorders in a human body, and also prevented developing microorganism resistance.

2 cl, 8 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium adolescentis PBB-3 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 218. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

Up!